Email this article Safe Use of Systemic Interferons for Multiple Sclerosis Treatment
- Authors: Snegireva I.I.1, Darmostukova M.A.1, Kazakov A.S.1, Lepakhin V.K.1
-
Affiliations:
- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- Issue: Vol 52, No 10 (2019)
- Pages: 863-864
- Section: Drugs
- URL: https://ogarev-online.ru/0091-150X/article/view/245514
- DOI: https://doi.org/10.1007/s11094-019-1916-8
- ID: 245514
Cite item
Open Access
Access granted
Subscription Access
Abstract
The safety of interferons was assessed by analyzing 499 spontaneous reports in the Russian database from 2015 to 2017. The results led to the conclusion that the safety profile of systemic interferon preparations that are widely used in medical practice to treat multiple sclerosis is defined by data in spontaneous reports for the development of adverse reactions to them or the ineffectiveness of using them.
About the authors
I. I. Snegireva
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Author for correspondence.
Email: SnegirevaII@expmed.ru
Russian Federation, 8/2 Petrovskii Blvd, Moscow, 127051
M. A. Darmostukova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Russian Federation, 8/2 Petrovskii Blvd, Moscow, 127051
A. S. Kazakov
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Russian Federation, 8/2 Petrovskii Blvd, Moscow, 127051
V. K. Lepakhin
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Russian Federation, 8/2 Petrovskii Blvd, Moscow, 127051
Supplementary files
